1.Clinical trial of myocardial protection using cold oxygenated diluted blood cardioplegia in child age.
The Korean Journal of Thoracic and Cardiovascular Surgery 1992;25(3):211-219
No abstract available.
Child*
;
Heart Arrest, Induced*
;
Humans
;
Oxygen*
5.A case of clear cell adenocarcinoma of the vagina.
Gum Noh LEE ; Kwan Soo KIM ; Young Hee KIM ; Hyung Ryul LEE ; Dong Kyu JEONG
Korean Journal of Obstetrics and Gynecology 1993;36(7):1033-1038
No abstract available.
Adenocarcinoma, Clear Cell*
;
Vagina*
6.Effect of fructose-1, 6-diphosphate(FDP) on red blood cells after extracorporeal circulation.
Jeong Ryul LEE ; Jong Myun HONG ; Yong Jin KIM ; Joon Ryang RHO ; Kyung Phill SUH
The Korean Journal of Thoracic and Cardiovascular Surgery 1992;25(7):693-701
No abstract available.
Erythrocytes*
;
Extracorporeal Circulation*
7.Total correction of tetralogy of Fallot in infancy.
Wan Ki BAEK ; Jeong Ryul LEE ; Yong Jin KIM ; Joon Ryang RHO ; Kyung Phil SUH
The Korean Journal of Thoracic and Cardiovascular Surgery 1991;24(2):115-122
No abstract available.
Tetralogy of Fallot*
8.Open heart surgery during the first 3 Months of life.
Kyung Phill SUH ; Joon Ryang RHO ; Yong Jin KIM ; Jeong Ryul LEE ; Tae Jin YUN
The Korean Journal of Thoracic and Cardiovascular Surgery 1993;26(3):180-185
No abstract available.
Heart*
;
Thoracic Surgery*
9.Expression of EGFR in Non-small Cell Lung Cancer and its Effects on Survival.
Tuberculosis and Respiratory Diseases 1997;44(6):1285-1295
BACKGROUND: EGFR is one of the initial step in signal transduction pathway about multistep carcinogenesis. It is homologous to oncogene erbB-2 and is the receptor for EGF and TGF alpha. EGFR has important role in the growth and differentiation of tumor cells. So, EGFR in non-small cell lung cancer was examined to search for possible evidence as clinical prognostic factor. METHODS: To investigate the role of EGFR in lung cancer, the author performed immunohistochemical stain of EGFR on 57 resected primary non-small cell lung cancer specimens. And the author analyzed the correlation between EGFR expression, clinical parameters, S and G1 phase fraction and survival. RESULTS: 1) EGFR were detected in 56% of total 57 patients (according to histologic type, squamous cancer 50%, adenocarcinoma 63%, large cell cancer 75%) (according to TNM stage, stage I 64%, stage II 38%, stage III 55%) (according to cellular differentiation, well 50%, moderately 52%, poorly 65%). All differences were insignificant. 2) Using the flow cytometric analysis, mean S-phase fraction of EGFR (+) and (-) group were 22.3(+/-10.5)%. 18.0(+/-10.9)% (p>0.05), mean G1-phase fraction of EGFR (+) and (-) group were 68.4(+/-11.6)%, 71.1(+/-12.8)%, (p>0.05) 3) Two-year survival rate of EGFR (+) and (-) group were 53%, 84%, median survival time of EGFR (+) and (-) group were 26, 53 months. (p<0.05, Kaplan-Meier, generalized Wilcox) CONCLUISON: EGFR immunostaining may be a simple and useful method for survival prediction in non-small cell lung cancer.
Adenocarcinoma
;
Carcinogenesis
;
Carcinoma, Non-Small-Cell Lung*
;
Epidermal Growth Factor
;
G1 Phase
;
Humans
;
Lung Neoplasms
;
Oncogenes
;
Signal Transduction
;
Survival Rate
10.Surgical treatment of patent ductus arteriosus in preterm and infants with severe heart failure and cardiac cachexia.
Seong Jae LEE ; Jeong Ryul LEE ; Yong Jin KIM ; Joon Ryang RHO ; Kyung Phill SUH
The Korean Journal of Thoracic and Cardiovascular Surgery 1993;26(12):915-919
No abstract available.
Cachexia*
;
Ductus Arteriosus, Patent*
;
Heart Failure*
;
Heart*
;
Humans
;
Infant*
Result Analysis
Print
Save
E-mail